ViiV to Acquire Rights to HIV Drugs Created With Shionogi

GlaxoSmithKline’s ViiV Healthcare agreed to buy the rights to HIV treatments the unit has developed with Shionogi, giving the Japanese drugmaker a 10 percent stake in ViiV as the companies prepare to seek approval of the most advanced medicine from the collaboration.
Bloomberg